{"id":"sa-001","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital mycotic infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL4303659","moleculeType":"Small molecule","molecularWeight":"334.42"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SA-001 works by inhibiting the SGLT2 receptor, which reduces glucose reabsorption in the kidneys and lowers blood glucose levels. This mechanism of action is similar to other SGLT2 inhibitors, such as canagliflozin and empagliflozin.","oneSentence":"SA-001 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:41.607Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05269810","phase":"PHASE2","title":"Clinical Study to Investigate the Efficacy of Orally Administered SA001 in Patients With Primary Sjögren's Syndrome","status":"COMPLETED","sponsor":"Samjin Pharmaceutical Co., Ltd.","startDate":"2020-05-29","conditions":"Primary Sjögren's Syndrome (pSS)","enrollment":28},{"nctId":"NCT05303961","phase":"PHASE1","title":"Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Samjin Pharmaceutical Co., Ltd.","startDate":"2016-06-07","conditions":"Healthy","enrollment":56},{"nctId":"NCT02470286","phase":"PHASE1","title":"A Phase 1 Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Samjin Pharmaceutical Co., Ltd.","startDate":"2015-06-29","conditions":"Healthy","enrollment":40},{"nctId":"NCT03723798","phase":"PHASE2","title":"Clinical Study to Investigate the Efficacy and Safety of Orally Administered SA001 in Patients With Dry Eye Syndrome.","status":"COMPLETED","sponsor":"Samjin Pharmaceutical Co., Ltd.","startDate":"2017-11-08","conditions":"Dry Eye Syndrome","enrollment":172},{"nctId":"NCT00401076","phase":"PHASE3","title":"A Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Pancreatic Exocrine Insufficiency","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-07","conditions":"Pancreatic Exocrine Insufficiency, Chronic Pancreatitis, Pancreatectomy","enrollment":80},{"nctId":"NCT00400842","phase":"PHASE3","title":"A Study of SA-001 to Treat Pancreatic Exocrine Insufficiency","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-05","conditions":"Exocrine Pancreatic Insufficiency, Chronic Pancreatitis","enrollment":274}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SA-001","genericName":"SA-001","companyName":"Abbott","companyId":"abbott","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SA-001 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}